Analysis of 699 adults followed for 24 years revealed that the rate of epigenetic clock acceleration—how quickly DNA methylation patterns indicate biological aging—independently predicts mortality risk beyond baseline biological age measurements. Participants whose multiple generations of epigenetic clocks advanced more rapidly faced significantly higher death risk, even after accounting for their starting epigenetic age and other risk factors. This represents a paradigm shift in longevity biomarkers. While static epigenetic age measurements have shown promise, tracking the velocity of biological aging appears far more predictive of health trajectories. The finding suggests that interventions should target not just achieving a younger biological age, but maintaining stable aging rates over time. However, the observational design cannot establish whether slowing epigenetic acceleration would directly extend lifespan. The 24-year follow-up period and multi-generational clock validation strengthen these findings considerably. For longevity-focused individuals, this research suggests that regular epigenetic testing to monitor aging velocity—rather than single-point assessments—may become the gold standard for personalized healthspan optimization and intervention timing.